We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Efforts to Contain SARS Showing Progress

By HospiMedica staff writers
Posted on 28 May 2003
Health measures designed to rein in the virus causing severe acute respiratory disease (SARS) are proving to be effective in many countries, according to scientists recently convened by the World Health Organization (WHO, Geneva, Switzerland) to review the latest data on the disease.

The consensus was that health measures that have contributed to this progress are the earliest possible detection and treatment of people suspected of having SARS, the immediate quarantining of all those who have had any contact with them, and early information and travel warnings to the public on areas with dangerous outbreaks of SARS.

The scientists found no evidence that insects or animals can spread the virus, and no evidence was found that infected individuals were able to spread the virus before becoming ill. More...
Data have confirmed that the virus is mainly spread by droplets from the sneezes and coughs of infected people to those who have been in close contact with them. People with SARS appear to be most infectious during the second week of illness. However, all cases should be treated as highly infectious from the very first symptom in order to minimize the possibility of transmission to others.

In a related development, German researchers have found that an experimental drug tested as a common cold remedy might be modified to fight the SARS virus. The drug, known as AG-7088, is in clinical trials for treatment of rhinovirus, which causes colds. The compound itself could not be used to treat SARS but it could represent a good starting point for designing a SARS drug, reported the researchers, from the University of Luebeck (Germany).


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.